Two Sigma Advisers
URGN icon

Two Sigma Advisers’s UroGen Pharma URGN Stock Holding History

Two Sigma Advisers’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-111,600
Closed -$2.23M – 2638
2025
Q3 		$2.23M Buy
+111,600
New +$2M ﹤0.01% 1098
2024
Q4 		– Sell
-24,500
Closed -$311K – 2541
2024
Q3 		$311K Sell
24,500
-400
-2% -$5.94K ﹤0.01% 1894
2024
Q2 		$418K Buy
24,900
+6,100
+32% +$86.8K ﹤0.01% 1957
2024
Q1 		$282K Buy
18,800
+500
+3% +$8.17K ﹤0.01% 2093
2023
Q4 		$275K Sell
18,300
-600
-3% -$7.79K ﹤0.01% 2132
2023
Q3 		$265K Buy
+18,900
New +$303K ﹤0.01% 2018
2019
Q2 		– Sell
-8,800
Closed -$325K – 2444
2019
Q1 		$325K Buy
8,800
+1,800
+26% +$75.5K ﹤0.01% 1961
2018
Q4 		$301K Sell
7,000
-1,100
-14% -$49.5K ﹤0.01% 1984
2018
Q3 		$383K Sell
8,100
-2,100
-21% -$97.6K ﹤0.01% 1893
2018
Q2 		$508K Buy
+10,200
New +$594K ﹤0.01% 1911

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Two Sigma Advisers's URGN Position: Q4 2025 in Review

Two Sigma Advisers sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 111,600 shares — an estimated $2.23M sold.

Two Sigma Advisers first reported a position in URGN in Q2 2018 and held it in 10 quarters. The position peaked at $2.23M in Q3 2025. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

  • Two Sigma Advisers reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 111,600 UroGen Pharma shares in Q4 2025, an estimated $2.23M.
  • Two Sigma Advisers first reported a position in UroGen Pharma in Q2 2018 and held it in 10 quarters.
  • Two Sigma Advisers's UroGen Pharma position peaked at $2.23M in Q3 2025.
  • 167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.